Imatinib (STI571 or CGP57148B) is an innovative treatment for tumours with a constitutively
activated form of c-ABL, c-KIT, or PDGFR. Such tumours include Philadelphia-chromosome-…

A comment on this article appears in" Comparative In vitro cellular data alone are insufficient
to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-…

BACKGROUND Lung ultrasonography (LUS) has emerged as a noninvasive tool for the
differential diagnosis of pulmonary diseases. However, its use for the diagnosis of acute …

Background The definition of ‘long-COVID syndrome’ (LCS) is still debated and describes
the persistence of symptoms after viral clearance in hospitalized or non-hospitalized patients …

BCR/ABL (Breakpoint Cluster Region protein/Abelson tyrosine-protein kinase 1) kinase
domain (KD) mutations represent the most frequently described mechanism of resistance to the …

… favoured near R 5 : accordingly, SU11248 and 13, carrying a fluorine and a difluoromethoxy
group, respectively, showed lower activity compared to SU5416 (with a chlorine atom in R 5 …

Background: Digital mammography clearly distinguishes gland tissue density from the overlying
nonglandular breast tissue coverage, which corresponds to the existing tissue between …

… for the integrity and accuracy of the data analysis.; R. Camerini, S. Capone, and AF wrote the
… R. Carsetti was a member of the COVITAR study steering committee. CI received financial …

Thyroid neoplasia is frequently associated with rearranged during transfection (RET) proto-oncogene
mutations that cause hyperactivation of RET kinase activity. Selective inhibition of …

To date the optimal antiviral treatment against severe coronavirus disease 2019 (COVID‐19)
has not been proven; remdesivir is a promising drug with in vitro activity against several …